Search Results

There are 3126 results for: content related to: Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis

  1. An optimal adaptive design to address local regulations in global clinical trials

    Pharmaceutical Statistics

    Volume 9, Issue 3, July/September 2010, Pages: 179–189, Xiaolong Luo, Weichung Joe Shih, S. Peter Ouyang and Robert J. DeLap

    Article first published online : 22 SEP 2010, DOI: 10.1002/pst.456

  2. An alternative phase II/III design for continuous endpoints

    Pharmaceutical Statistics

    Volume 10, Issue 2, March/April 2011, Pages: 105–114, Wong-Shian Huang, Jen-pei Liu and Chin-Fu Hsiao

    Article first published online : 22 FEB 2010, DOI: 10.1002/pst.418

  3. Effects of unstratified and centre-stratified randomization in multi-centre clinical trials

    Pharmaceutical Statistics

    Volume 10, Issue 1, January/February 2011, Pages: 50–59, Vladimir V. Anisimov

    Article first published online : 28 JAN 2010, DOI: 10.1002/pst.412

  4. Assessing departure from dose linearity under a repeated measures incomplete block design

    Pharmaceutical Statistics

    Volume 10, Issue 4, July/August 2011, Pages: 357–362, Bin Cheng and Shein-Chung Chow

    Article first published online : 22 NOV 2010, DOI: 10.1002/pst.474

  5. Sample size and proportion of Japanese patients in multi-regional trials

    Pharmaceutical Statistics

    Volume 9, Issue 3, July/September 2010, Pages: 207–216, Kimitoshi Ikeda and Frank Bretz

    Article first published online : 22 SEP 2010, DOI: 10.1002/pst.455

  6. Confirmatory analysis for phase III population pharmacokinetics

    Pharmaceutical Statistics

    Volume 10, Issue 1, January/February 2011, Pages: 14–26, Chuanpu Hu, Ji Zhang and Honghui Zhou

    Article first published online : 29 DEC 2009, DOI: 10.1002/pst.403

  7. Block response-adaptive randomization in clinical trials with binary endpoints

    Pharmaceutical Statistics

    Volume 10, Issue 4, July/August 2011, Pages: 341–346, Dominic Magirr

    Article first published online : 9 NOV 2010, DOI: 10.1002/pst.471

  8. Increasing the sample size at interim for a two-sample experiment without Type I error inflation

    Pharmaceutical Statistics

    Volume 9, Issue 4, October/December 2010, Pages: 280–287, Keith Dunnigan and Dennis W. King

    Article first published online : 17 SEP 2009, DOI: 10.1002/pst.390

  9. Sample size re-estimation for survival data in clinical trials with an adaptive design

    Pharmaceutical Statistics

    Volume 10, Issue 4, July/August 2011, Pages: 325–331, Kanae Togo and Manabu Iwasaki

    Article first published online : 28 OCT 2010, DOI: 10.1002/pst.469

  10. Adapting by calibration the sample size of a phase III trial on the basis of phase II data

    Pharmaceutical Statistics

    Volume 10, Issue 2, March/April 2011, Pages: 89–95, Daniele De Martini

    Article first published online : 8 FEB 2010, DOI: 10.1002/pst.410

  11. Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongation

    Pharmaceutical Statistics

    Volume 10, Issue 3, May/June 2011, Pages: 265–276, Robert Schall and Arne Ring

    Article first published online : 26 OCT 2010, DOI: 10.1002/pst.463

  12. Assessing non-inferiority to an aggregate response with an application to development of pneumococcal conjugate vaccines

    Pharmaceutical Statistics

    Volume 10, Issue 4, July/August 2011, Pages: 332–340, Yi Pan, Guanghan F. Liu and Michael J. Dallas

    Article first published online : 9 NOV 2010, DOI: 10.1002/pst.470

  13. The role of the minimum clinically important difference and its impact on designing a trial

    Pharmaceutical Statistics

    Volume 10, Issue 3, May/June 2011, Pages: 250–256, Christy Chuang-Stein, Simon Kirby, Ian Hirsch and Gary Atkinson

    Article first published online : 8 OCT 2010, DOI: 10.1002/pst.459

  14. Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data

    Pharmaceutical Statistics

    Volume 9, Issue 4, October/December 2010, Pages: 313–330, Shuying Yang and James Roger

    Article first published online : 30 DEC 2009, DOI: 10.1002/pst.400

  15. Sample-size calculations for multi-group comparison in population pharmacokinetic experiments

    Pharmaceutical Statistics

    Volume 9, Issue 4, October/December 2010, Pages: 255–268, Kayode Ogungbenro and Leon Aarons

    Article first published online : 27 AUG 2009, DOI: 10.1002/pst.388

  16. Estimation of the limit of detection for quantal response bioassays

    Pharmaceutical Statistics

    Volume 10, Issue 3, May/June 2011, Pages: 203–212, Edwin van den Heuvel

    Article first published online : 4 MAY 2010, DOI: 10.1002/pst.435

  17. Graphical displays for clarifying how allocation ratio affects total sample size for the two sample logrank test

    Pharmaceutical Statistics

    Volume 10, Issue 1, January/February 2011, Pages: 40–44, Benjamin R. Saville, Yong S. Kim and Gary G. Koch

    Article first published online : 14 JAN 2010, DOI: 10.1002/pst.407

  18. You have full text access to this OnlineOpen article
    Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies

    Pharmaceutical Statistics

    Volume 10, Issue 2, March/April 2011, Pages: 150–161, Peter C. Austin

    Article first published online : 27 APR 2010, DOI: 10.1002/pst.433

  19. A flexible class of models for data arising from a ‘thorough QT/QTc study’

    Pharmaceutical Statistics

    Volume 10, Issue 2, March/April 2011, Pages: 122–127, Suraj P. Anand and Sujit K. Ghosh

    Article first published online : 22 MAR 2010, DOI: 10.1002/pst.420

  20. Investigating the assumption of homogeneity of treatment effects in clinical studies with application to meta-analysis

    Pharmaceutical Statistics

    Volume 11, Issue 1, January/February 2012, Pages: 49–56, Steven A. Julious and Anne Whitehead

    Article first published online : 2 DEC 2011, DOI: 10.1002/pst.494